innoviCares in the News: THe Future of Prescription Drugs Special Report – The Globe & Mail

STI was featured in The Globe & Mail’s Special Report on The Future of Prescription Drugs with a full page ad and page of editorial content on patient choice and innoviCares. The editorial includes interviews with patients, physicians, patient advocates and STI’s CEO, Steve Nicolle. The ad and article are part of the 8 page Special Report which is included in every Globe & Mail newspaper across Canada. To view the PDF of the article, Click Here.

Free Drug Benefit Plan Supports Over Half a Million Canadians

InnoviCares, Canada’s only free multi-drug manufacturer patient benefit plan, marked their 600,000 member on April 28, 2014, and their participation rates show signs of acceleration through increasing partnerships and widespread patient satisfaction.

“We are extremely pleased with the growth of innoviCares. Since its launch in January 2013, innoviCares has already grown to bring together 18 different drug manufacturers and nearly 100 products covered,” said Steve Nicolle, CEO of STI Technologies Ltd, innoviCares parent company. “By complementing public and private drug plans through greater access to original brand name medications, we are improving health outcomes and adherence rates for many patients, and at no additional cost to them.”

Employers, associations, physicians, and pharmacists have widely embraced the program, and for countless patients innoviCares offers significant financial savings and stability in their healthcare.

STI Technologies Limited was recently visited by Troy Wellington, an innoviCares member from Barrie, Ontario, who stressed the positive impact that the plan has had in his family’s life. “You don’t think that something so small could make such a big, drastic change in a person’s life, but it did. Emotionally stable, mentally stable, physically stable… The financial burden was lifted from my wife’s shoulders for those medications.”

InnoviCares supports a patient’s choice to remain on original brand name medication by paying towards the cost difference between brand and the generic alternative.

“Reaching out for medical assistance when a person has reasons to believe they may be experiencing mental health concerns is extremely important,” says Dave Gallson, Associate National Executive Director for Moods Disorders Society of Canada. “Working with your Doctor or healthcare professional, proper diagnosis and a care plan which often includes finding the appropriate medication can make a significant impact in a patient’s continued health and well-being.  Thanks to innoviCares, patients have access to brand medication at the same price of a generic.”

STI Privacy Policy Update

The corporate STI Technologies Limited Privacy Policy has been updated as of today. These updates will go into effect immediately.

STI Technologies Limited respects your concerns about privacy and takes the protection of information very seriously. That commitment to our users hasn’t changed.

Here is a quick overview of the changes:

  • To assist you in making an informed decision when using our site and services, we’ve rewritten our policy with clearer language.4We’ve added a Customer Service section. In a nutshell, it means that if you contact our customer service team, we will retain some basic information, for example, your name and phone number, so we can better serve you should you reach out again.
  • To reflect how we may use content for marketing (or other) purposes, we’ve added a Social Media and Website section.
  • In addition, we’re including a section on Google Analytics, which we will use to monitor our website’s traffic. (Learn more about Google Analytics.)

We don’t sell your personal information to third parties and we comply with all Canadian federal and provincial privacy laws.

If you have any questions about these updates, please contact us at 1-877-790-1991 or email privacyofficer@smartsti.com.

Page 2 of 212